NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Thanks Survivor1x.

Article: Predicting analysis times in randomized clinical trials with cancer immunotherapy.

“A new class of immuno-oncology agents has recently been shown to induce long-term survival in a proportion of treated patients. This phenomenon poses unique challenges for the prediction of analysis time in event-driven studies. If the phenomenon of long-term survival is not accounted for properly, the accuracy of the prediction based on the existing methods may be substantially compromised.”


“Given that a subset of the patients is no longer at risk of the event of interest, such as disease recurrence or death, the study duration could be substantially longer than what is anticipated if this phenomenon is not accounted for or is misspecified at the study design stage.”

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736164/